Attention-deficit/hyperactivity disorder
Синдром дефицита внимания с гиперактивностью
2015-08-05
SCID: 54.1/jtjs9wu6
Discuss with AI
attention-deficit/hyperactivity disorderevidence-based treatmentneurocognitive impairmentneurodevelopmental disorderpsychiatric comorbidity
Figures from the paper
Abstract (AI)
Attention-deficit/hyperactivity disorder (ADHD) is a persistent neurodevelopmental disorder that affects 5% of children and adolescents and 2.5% of adults worldwide. Throughout an individual's lifetime, ADHD can increase the risk of other psychiatric disorders, educational and occupational failure, accidents, criminality, social disability and addictions. No single risk factor is necessary or sufficient to cause ADHD. In most cases ADHD arises from several genetic and environmental risk factors that each have a small individual effect and act together to increase susceptibility. The multifactorial causation of ADHD is consistent with the heterogeneity of the disorder, which is shown by its extensive psychiatric co-morbidity, its multiple domains of neurocognitive impairment and the wide range of structural and functional brain anomalies associated with it. The diagnosis of ADHD is reliable and valid when evaluated with standard criteria for psychiatric disorders. Rating scales and clinical interviews facilitate diagnosis and aid screening. The expression of symptoms varies as a function of patient developmental stage and social and academic contexts. Although there are no curative treatments for ADHD, evidenced-based treatments can markedly reduce its symptoms and associated impairments. For example, medications are efficacious and normally well tolerated, and various non-pharmacological approaches are also valuable. Ongoing clinical and neurobiological research holds the promise of advancing diagnostic and therapeutic approaches to ADHD. For an illustrated summary of this Primer, visit: http://go.nature.com/J6jiwl.
Key Findings
1
ADHD is a persistent neurodevelopmental disorder affecting approximately 5% of children and adolescents and 2.5% of adults worldwide.
2
ADHD typically results from multiple genetic and environmental risk factors, each exerting small effects that jointly increase susceptibility.
3
Evidence-based treatments, including medications and non-pharmacological approaches, can substantially reduce ADHD symptoms and associated impairments, although no curative treatment exists.
4
Standard psychiatric diagnostic criteria provide reliable and valid ADHD diagnosis, supported by rating scales and clinical interviews.
5
The disorder is heterogeneous, involving substantial psychiatric comorbidity, diverse neurocognitive impairments, and varied structural and functional brain anomalies.
Research Object
Attention-deficit/hyperactivity disorder (ADHD)
Research Subject
The multifactorial causes, clinical heterogeneity, diagnosis, symptom expression, associated impairments, and treatment of ADHD
Publication Details
Publication Date
2015-08-05
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis2015
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD2010
Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder2010
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis2009
Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation2007
Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders1991
Cited by4
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder2021
Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder2018
Updated European Consensus Statement on diagnosis and treatment of adult ADHD2018
Genetics of attention deficit hyperactivity disorder2018